Daily News Podcast

Finally, new migraine drugs

Publish date: August 1, 2018

 

Successful phase 3 data for new headache medications (rimegepant, ubrogepant, lasmiditan) are finally raining in after a lengthy drought. Also today, interferon status and family history predict autoimmune connective tissue disease, steroid injection before rotator cuff repair predicts revision, and the CMS resumes risk adjustment payments for 2017. Listen to the MDedge Daily News for today’s top news.

Recommended Reading

Managing HIV with diabetes
MDedge Rheumatology
Telemedicine payment expansion?
MDedge Rheumatology
Bundle pay plan didn’t save money
MDedge Rheumatology
Brain damage, slight benefit seen in epinephrine cardiac arrest
MDedge Rheumatology
Is fibromyalgia one disorder – or two?
MDedge Rheumatology
Is fish oil’s heart benefit a fish tale?
MDedge Rheumatology
Blood pressure meds cut cognitive impairment risk
MDedge Rheumatology
Antibody cleared amyloid plaques, slowed cognitive decline
MDedge Rheumatology
Free skin cancer screening highlights need
MDedge Rheumatology
Valsartan cancer risk is low
MDedge Rheumatology